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ABSTRACT 
Aims: To describe temporal trends in adoption and performance of transcatheter aortic valve 
implantation (TAVI) in Switzerland over a period of 5 years. 
Methods and Results: Between 2011 and 2015, a total of 3’493 patients were consecutively included 
in the SwissTAVI Registry (NCT01368250) and analyzed for the purpose of this study. The primary 
outcome measure was all-cause mortality at 1-year after TAVI. Over the five-year period, a six-fold 
increase in the number of procedures was observed, whereas the baseline surgical risk estimated by 
the Society of Thoracic Surgeon (STS) score declined (from 6.8 ± 4.4% to 4.6 ± 3.6, p<0.001). Overall, 
1-year mortality amounted to 12.8%; mortality was highest in the first annual cohorts (14.6%, 14.8%
and 15.9% in 2011, 2012 and 2013, respectively) and decreased to 13.4% in 2014 and 9.7% in 2015, 
with a significant temporal trend. While rates of cerebrovascular events, peri-procedural myocardial 
infarction, moderate/severe paravalvular regurgitation and stage 3 acute kidney injury did not 
significantly change over time, a significant reduction in life threatening or major bleeding was noted 
during the latest compared with earlier years of recruitment.  
Conclusions: This long-term recruitment analysis of a national TAVI registry showed rapid adoption 
paralleled by a progressive decrease of patients’ baseline risk profile. Early and late survival 
significantly improved over time as did the rate of life threatening or major bleeding.  
Key words: aortic stenosis, transcatheter aortic valve implantation, mortality, trends 
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INTRODUCTION 
During the past 15 years, transcatheter aortic valve implantation (TAVI) has transformed the treatment 
of patients with symptomatic, severe aortic stenosis and assumed a Class I recommendation for use in 
patients at increased surgical risk.1 TAVI has demonstrated superiority over conservative therapy in 
inoperable patients 2 and non-inferiority or superiority compared with surgical aortic valve 
replacement in patients at high or intermediate operative risk.3-6 As for other innovative procedures, 
randomized trials and observational studies provide complementary evidence to support the 
expansion of TAVI.7 Specifically, the contribution of nationwide registries is key to assess patterns of 
changing patient characteristics, procedural features and clinical outcomes in routine clinical practice.8-
12 In addition, comprehensive recording of procedures within national registries is essential for a 
comparative evaluation of the quality of care of heart valve centers as well as for setting new 
performance goals.1 
The SwissTAVI Registry (NCT01368250) is a national, prospective registry initiated by the Swiss 
Working Group of Interventional Cardiology in collaboration with the Swiss Society of Cardiac Surgery 
with the aim to assess the safety and effectiveness of consecutive TAVI procedures performed in 
Switzerland since 2011. In-hospital and 30-day clinical outcomes of patients included between 
February 2011 and March 2013 have been previously presented.13 This report describes temporal 
trends in TAVI volume and performance during a 5-year period and reports on the primary outcome 
measure of major adverse cardiac and cerebrovascular events since the initiation of the registry over 
time. 
METHODS 
Design and setting 
The SwissTAVI Registry is performed under the lead of the Swiss Cardiovascular Center Bern at Bern 
University Hospital and is based on the collection of clinical, procedural and follow-up data of 
consecutively included patients undergoing TAVI at 14 sites (Supplemental Table S1). A 
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multidisciplinary heart team is responsible for the decision to perform TAVI at each participating site. 
The use of CE-approved devices is mandatory while the type of access route is left to operators’ 
discretion. The SwissTAVI Registry aims to assess the rates of major adverse cardiac and 
cerebrovascular events at one-year (primary outcome). 
Data collection 
A web-based database (www.swisstavi.ch) with standardized case-report forms is used for 
anonymized data collection at baseline and during follow-up that is performed through scheduled 
clinical visits or phone interviews at 30-days and annually after the procedure. Clinical events occurring 
during the procedure or follow-up are blinded for patient details and the performing center and are 
adjudicated following review of original source documents by a dedicated clinical event committee. 
The SwissTAVI Clinical Event Committee consists of interventional cardiologists and cardiac surgeons 
and events are assessed and adjudicated according to the updated criteria of the Valve Academic 
Research Consortium (VARC-2).14 The Clinical Trials Unit Bern is responsible for central data monitoring 
to verify completeness and accuracy of data and independent statistical analysis. The study protocol 
was approved by the local cantonal ethic committee at each site and all patients provided written 
informed consent before inclusion. 
Study endpoints 
The primary study endpoint of the present analysis is all-cause mortality 1-year after the procedure. 
Secondary endpoints include cardiovascular mortality, cerebrovascular accident, myocardial 
infarction, stage 3 acute kidney injury (AKI), life threatening or major bleeding, vascular access site 
complications, structural valve deterioration and repeat unplanned intervention. In addition, 
standardized mortality ratios (SMRs) were calculated to compare trends in mortality of TAVI patients 
compared with an age- and gender-matched general population during the respective year of 
treatment (downloaded from Bundesamt für Statistik, Switzerland).15 
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Statistical analysis 
Continuous and categorical variables are reported as mean ± standard deviation and as number and 
percentage, respectively. 30-day event rates are reported using time-to-first-event data, graphically 
presented using Kaplan-Meier curves, with incidence rates calculated from life tables. Baseline patient 
clinical characteristics and procedural feature by calendar year were compared using ANOVA, Kruskall-
Wallis or Chi-square tests (categorical variables). Event rates at 30 days and 1 year were compared 
through the 5-year period (2011-2016) using Weibull regressions with a shared frailty by hospital (14 
sites). Reported are crude hazard ratio (HR, with 95% confidence intervals, CI) and p-value testing for 
an overall linear trend over the 5-year period from Weibull regression, or overall difference from 
Fisher’s exact test in case of zero events. Reported are adjusted hazard ratios (HRadj, with 95% 
confidence intervals, CI) for comparisons including adjustment for the STS-PROM (Society of Thoracic 
Surgeons-Predicted Risk Of Mortality) score and type of access route. Adjusted p-values testing for an 
overall linear trend over the five periods.  
SMR is an epidemiologic measure that describes the impact disease has on the likelihood of death 
compared with the general population. The indirect SMRs (adjusted for age and sex) (with exact 95% 
confidence intervals [95% CIs]) in the three study cohorts, as compared to the general population, 
were determined by calculating the ratio of the observed mortality rate to the expected mortality rate 
within the same period of time, using the method described by Ulm.15 Observed deaths referred to the 
actual number of deaths of patients. Expected deaths referred to the number of deaths expected from 
the population statistics within the same period (year), stratified by sex and age. The age- and sex-
specific mortality rates in the general population were obtained from the Swiss Bundesamt für Statistik 
matched on year of procedure. All analyses were performed using Stata (version 14.2; StataCorp LP, 
College Station, TX). Statistical significance was determined by a 2-sided p<0.05. 
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RESULTS 
Demographic and clinical patient characteristics 
From February 15, 2011 to February 15, 2016, 3’493 consecutive patients were prospectively included 
in the SwissTAVI Registry. Annual procedural rates increased approximately linearly from 208 in 2011 
to 1’254 in 2015. At the same time the STS-PROM score gradually decreased (from 6.8 ± 4.4% in 2011 
to 4.6 ± 3.6% in 2015, p<0.001). While a numerical increase of the STS PROM was observed between 
2011 and 2013 (p=0.64), the significant decrease during the overall observational period was mainly 
related to the last 2 years of patient inclusion. (Figure 1). Table 1 shows baseline characteristics over 
time. Mean age of the overall population was 82.1 ± 6.4 years and remained stable during the years. 
There were also no significant differences in sex, diabetes mellitus, coronary artery disease, previous 
cardiac surgery and left ventricular ejection fraction. However, patients that underwent TAVI in the 
latest compared with earlier years of recruitment had less often chronic obstructive pulmonary disease 
as well as New York Heart Association (NYHA) functional class III or IV.  
Procedural characteristics  
As reported in Table 2, trends in the use of different CE-approved transcatheter heart valves changed 
over time. Overall, the Medtronic self-expanding (CoreValve and Evolut R, Medtronic, Minneapolis, 
Minnesota) and the Edwards balloon-expandable (Sapien THV/XT and Sapien 3, Edwards Lifesciences, 
Irvine, California) transcatheter heart valves were most commonly used. The proportion of patients 
undergoing balloon aortic valvuloplasty during the index procedure before valve implantation 
decreased from 93.8% in 2011 to 54.9% in 2015 (p<0.001). 
The use of the transfemoral access progressively increased up to 92.1% of procedures performed in 
2015; consistently, rates of procedures performed by means of other access routes, including 
transapical, trans-subclavian and direct aortic, declined over time (Figure 2). Concomitant coronary 
revascularization was less frequently performed in the latest compared with earlier years of 
recruitment. 
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A significant decrease in procedural time and total amount of contrast volume was observed over time. 
Overall, rates of procedural complications requiring conversion to surgery remained very low over the 
years. Mean length of index hospitalization significantly decreased from 2011 to 2015.  
Clinical outcomes  
Overall, all-cause mortality was observed at a rate of 3.8% at 30-day follow-up. It was highest in 2011 
(5.8%) and steadily decreased to 4.6% in 2012, 4.9% in 2013, 4.0% in 2014 and 2.5% in 2015, with a 
significant temporal trend (p= 0.02). Figure 3 shows rates of observed and expected mortality, as 
calculated by the STS-PROM scoring system. Cardiac mortality decreased by half over the years (HRadj 
0.86, 95% CI 0.75-0.99, p= 0.034). 
Rates of primary and secondary study endpoints are reported in Table 3. Figure 4 shows rates of events 
occurring within 30-days after TAVI for each year of recruitment: cerebrovascular events, myocardial 
infarction, and moderate/severe paravalvular regurgitation did not significantly change over time.  Life 
threatening or major bleeding events occurred less frequently in the latest compared with earlier years 
of recruitment (HRadj 0.92, 95% CI 0.85-0.99, p= 0.033). Overall, permanent pacemaker implantation 
was needed in 18.6% of patients: while rates of pacemaker implantation after TAVI with balloon-
expandable devices were stable over the time (Table 3), a progressive reduction was observed in 
patients treated with self-expanding devices (Supplemental Table S2). The decrease of rates of stage 
3 AKI across years was not significant in adjusted analysis. 
All-cause mortality at one year occurred in 12.8% of patients and was highest in 2011 (14.6%), 
2012 (14.8%) and 2013 (15.9%) and decreased to 13.4% in 2014 and 9.7% in 2015, with a significant 
temporal trend (p<0.001). Similarly, the overall rate of cardiac mortality was higher in 2011 (10.4%), 
2012 (10.9%) and 2013 (11.0%) and decreased to 9.9% in 2014 and 6.1% in 2015, with a significant 
temporal trend also after adjustment for confounders (HRadj 0.90, 95C% CI 0.82-0.99, p= 0.033). 
Kaplan-Meier curves of all-cause and cardiac mortality at 1-year are shown in Figure 5A and B. Rates 
of cerebrovascular events, myocardial infarction, structural valve deterioration and repeat unplanned 
valvular interventions were comparable across the years.  
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Mortality after TAVI compared with the general population in Switzerland 
In the overall TAVI patient population, SMRs were found to be four-fold higher throughout the 
observational period and were highest among male patients when compared with an age- and gender 
matched general population in Switzerland. However, we observed a statistical trend towards a 
reduction of SMRs as shown in Figure 6. Specifically, the SMRs of the entire cohort were 3.81 (95% CI 
2.66-5.45) in 2011, 4.56 (95% CI 3.61-5.76) in 2012, 5.03 (95% CI 4.11-6.16) in 2013, 4.96 (95% CI 4.16-
5.91) in 2014 and 3.75 (95% CI 3.13-4349) in 2015. Among males, the SMRs were 3.83 (95% CI 2.27-
6.46) in 2011, 5.08 (95% CI 3.73-6.93) in 2012, 5.52 (95% CI 4.18-7.29) in 2013, 6.02 (95% Ci 4.79-7.58) 
in 2014 and 4.97 (95% CI 3.96-6.23) in 2015. Similarly, the SMRs for female patients were 3.79 (95% CI 
2.32-6.19) in 2011, 3.97 (95% CI 2.78-5.68) in 2012, 4.59 (95% CI 3.42-6.17) in 2013, 3.97 (95% CI 3.03-
5.21) in 2014 and 2.62 (95% CI 1.95—3.54) in 2015.  
DISCUSSION 
The salient findings of our study investigating temporal trends in adoption and performance of TAVI 
in Switzerland can be summarized as follows:  
- TAVI was rapidly adopted in Switzerland with an annual increase in procedure rates and a
significant decrease in the estimated risk profile
- The use of transapical and other alternative access routes progressively declined in favor of
the transfemoral access
- We observed a relevant decrease in procedural duration and length of index hospitalization
over time
- Life threatening or major bleeding declined over the years, whereas rates of other procedure-
related complications remained stable
- All-cause and cardiac mortality were significantly lower in the latest compared with earlier
years of patient treatment
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- Overall, patients undergoing TAVI had a four-fold increased risk of mortality compared with an
age- and gender-matched general population
The observed increase of annual TAVI procedures is in line with the global trend of TAVI dissemination 
with a projected more than four-fold increase in volume over the next 10 years.7 Population ageing, 
increased awareness of the disease and robust evidence of clinical benefit of the procedure in a broad 
spectrum of patients with severe aortic stenosis are the major drivers of this expansion.  
Along the same line, the tendency to treat lower risk patients is consistent with other registries: a steep 
decrease in the logistic EuroSCORE was reported between patients included in the FRANCE 2 and 
FRANCE TAVI in 2010-2012 and 2013-2015, respectively;16 an increasing proportion of 
intermediate/low-risk patients over time was observed in the German TAVI registry;10 among 26,414 
patients in the Society of Thoracic Surgeons (STS)/American College of Cardiology (ACC) Transcatheter 
Valve Therapy (TVT) Registry, a significant decline of the STS-PROM occurred from 2012-2013 to 2014.8 
A multitude of reasons may explain this common trend that occurred prior to the results of randomized 
trials in lower risk patients were made available.5, 6 First of all, accumulating evidence of favorable 
clinical and hemodynamic results of TAVI from observational studies may have favored its adoption in 
lower risk patients.17, 18 In addition, factors other than the classical surgical risk scores are increasingly 
considered by multidisciplinary heart teams for the choice between TAVI and surgery (frailty, geriatric 
assessment). In this context, it is important to note that the mean age amounted to 82 years and did 
not significantly decrease despite a decrease in STS risk scores.19 The tendency to treat elderly but 
lower risk patients is influenced by the evidence provided from the pivotal TAVI trials: in the 
randomized comparisons with surgery, high- and intermediate-risk cohorts were defined on the basis 
of the mean STS score, whereas the mean age of included patients continued to reflect an elderly 
population (over 80 years of age ). 19 Ongoing studies investigating clinical outcomes after TAVI in low-
risk patients will focus for the first time on the comparative performance also in younger patients. 
There is no age restriction for the inclusion in the PARTNER 3 (NCT02675114) and in the Medtronic 
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Low risk trial (NCT02701283) and also NOTION-2 includes patients at the age of 75 or younger 
(NCT02825134). A change in clinical practice is expected on the basis of the results of these studies.  
Furthermore, different policies for reimbursement of TAVI procedures may influence the 
evolution of patients’ characteristics over time across different countries. In the United Kingdom, only 
minimal changes in the baseline profile of patients treated from 2007 and 2012 were observed, 
probably as consequence of a position statement from regulators of health care that restricted the 
funding to patients with Logistic EuroSCORE >20 and STS-PROM score >10.20 Overall, increasing 
procedure volume and changing features of patients receiving TAVI concur to ameliorate clinical 
outcomes. Similarly, in the TVT Registry, an association between procedure volume and risk-adjusted 
outcomes was reported from 2011 to 2015, with early mortality, vascular complications and bleeding 
events significantly declining from the first to the 400th case.21 Finally, the STS score undergoes regular 
updates and calculation of the risk score today differs from calculations performed several years ago. 
Transfemoral TAVI has emerged as the preferred strategy over the 5-year period and rates of 
transfemoral TAVI procedures progressively increased over time. The reason for this increase is most 
likely reflected by the ongoing development of TAVI devices. The availability of innovative devices 
featuring lower profiles of delivery systems contribute to enlarge the proportion of patients whose 
anatomic features are suitable for transfemoral procedures. This trend was observed in previous 
reports,8, 10 and may have influenced clinical outcomes in successive years. Cumulative evidence from 
randomized trials showed a significant survival advantage of TAVI performed through transfemoral 
rather than other access routes over conventional surgery.22 Similarly, the reduction in procedure 
duration and length of hospitalization may be attributed to technological improvement, growing 
operator experience and the lower operative risk of patients.  
Although site-reported, all clinical events recorded in the SwissTAVI Registry are adjudicated based on 
clinical source documents by a clinical event committee consisting of cardiologists and surgeons. This 
represents one of the major strengths with respect to other registries. In this context, it is reassuring 
that rates of the most debilitating peri-procedural adverse events such as cerebrovascular events and 
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myocardial infarction remained low over time. In particular, 30-day rates of stroke during the most 
recent years (1.7% in 2014 and 2015) represent the lowest rate reported so far, within randomized 
and observational studies. The lack of a further reduction of cardiac and cerebrovascular ischemic 
event rates over time, despite a more favorable risk profile of patients, can be explained by the fact 
that procedure- rather than patient-related factors may have a greater impact on the occurrence of 
such events. In this perspective, the use of a transfemoral access first strategy and preventive coronary 
revascularization in patients with significant disease of proximal segments of main coronary vessels 
may have ensured the lowest rates of stroke and myocardial infarction, so far. Stage 3 AKI also declined 
throughout the study period, probably as result of procedural advances (reduction of contrast volume, 
lower use of balloon valvuloplasty) and more favorable profile of patients at baseline. Although the 
trend was not significant after adjustment for confounders, low occurrence of post-procedural renal 
dysfunction may have a positive impact on clinical outcomes, given the well-known association of 
advanced acute renal injury with higher risk of mortality and re-hospitalization.23, 24 Similarly, the 
observed significant reduction of early life-threatening or major bleeding events may have contributed 
to ameliorate 30-day survival over time.  
In the entire population, moderate/severe paravalvular regurgitation and the need for PPM 
after TAVI occurred in 5.6% and 18.6% of patients, respectively, without significant changes during the 
following years. These are actually considered the current main limitations of TAVI compared with 
surgery and might be related to certain devices features. It should be noted that our observations are 
limited at years between 2011 and 2015 while the most frequent generation of devices (Edwards 
Sapien 3, Medtronic Evolut R) were only introduced in 2014. However, although the frequency of these 
events is well within the range of other reported TAVI series,16, 20 a further decline in rates is warranted. 
Several lines of evidence support the association between more than mild residual paravalvular 
regurgitation and an increased risk of mortality, also in intermediate risk patients.5 In addition, 
although there is conflicting evidence on the impact of PPM implantation on survival, sustained loss of 
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atrioventricular synchrony by chronic pacing may affect cardiac function at longer term, especially in 
younger patients.25 
Rates of 30-day and 1-year mortality (3.8% and 12.8%, respectively) in the overall population were 
significantly lower than those observed in other registries8, 20 but compare favorably with the results 
of recent randomized trials such as the PARTNER 2A (3.9% and 12.3%, respectively).5 The low rates of 
mortality in 2015 (2.5% at 30-day and 9.7% at 1-year) provide reassurance about the safety and efficacy 
of the procedure among lower risk patients and set a benchmark that should inform the decision 
process of local heart teams and patient counselling.  
Limitations 
The results of the present study should be interpreted taking into account the following limitations. 
The description of temporal trends and associations does not provide evidence of causality. Moreover, 
we were not able to assess the impact of the learning curve of operators across centers participating 
into the registry on clinical outcomes after TAVI. Finally, as adverse event reporting is left to the 
discretion of each site, a certain underreporting of events and bias cannot be excluded. 
Conclusions 
This long-term recruitment analysis of a national TAVI registry showed rapid adoption paralleled by a 
progressive decrease of patients’ baseline risk profile. Early and late survival significantly improved 
over time as did the rate of life threatening or major bleeding.  
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Figure Legends 
Figure 1. Cumulative TAVI procedures and STS-PROM score of patients included in the SwissTAVI 
Registry from 2011 to 2015. 
Since the initiation of the registry in 2011, there was a rapid expansion of annual rates of procedures paralleled 
by a progressive change in baseline risk profile of patients. 
STS-PROM, The Society of Thoracic Surgeons- Predicted Risk Of Mortality; TAVI, Transcatheter aortic valve implantation. 
Figure 2. Temporal trends of access routes for TAVI.  
Progressive increase of transfemoral approach (blue line) and parallel decrease of use of other access routes 
(including transcapical, direct aortic and trans-subclavian, red line) for TAVI.  
TAVI, Transcatheter aortic valve implantation. 
Figure 3. Observed and expected rates of mortality (STS PROM) (upper panel); Ratio of observed vs. 
expected rates of mortality (lower panel) by year of inclusion in the SwissTAVI Registry. 
Figure 4. Rates of procedure-related and other early adverse event across study years.  
From 2011 to 2015, rates of stroke, myocardial infarction, stage 3 acute kidney injury, and moderate/severe 
paravalvular regurgitation did not significantly change over the time. Rates of life-threatening or major bleeding 
significantly decreased in subsequent years. AKI, Acute Kidney Injury; PVL, Paravalvular leak. 
Figure 5. Mortality at 1-year in patients included in the SwissTAVI Registry between 2011 and 2015. 
Kaplan-Meier curves of all-cause (A) and cardiac (B) mortality at 1-year after TAVI according to the year of 
inclusion in the registry. 
Figure 6. SMRs of TAVI patients.  
Age- and sex-adjusted standardized mortality ratios (SMRs) of TAVI patients (overall population and stratified by 
gender). Results are shown as the SMR with 95% confidence intervals. 
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Table Legends 
Table 1. Baseline characteristics per year of inclusion 
Table 2. Procedural characteristics per year of inclusion 
Table 3. Clinical outcomes at 30-day and 1-year after TAVI per year of inclusion 
TABLE 1. Baseline characteristics per year of inclusion 
All years 2011 2012 2013 2014 2015 p-value
N = 3493 N = 208 N = 474 N = 596 N = 961 N = 1254 
Age (years) 82.1±6.4 82.4±5.6 82.3±6.3 82.3±6.4 82.1±6.5 82.0±6.6 0.80 
Female gender, n(%) 1733 (49.6%) 112 (53.8%) 245 (51.7%) 287 (48.2%) 469 (48.8%) 620 (49.4%) 0.54 
Body mass index (kg/m2) 26.6±5.1 26.5±5.1 26.2±4.8 26.6±5.0 26.8± 5.2 26.6±5.2 0.33 
Diabetes mellitus, n(%) 885 (25.3%) 61 (29.3%) 136 (28.7%) 144 (24.2%) 238 (24.8%) 306 (24.4%) 0.21 
Previous PPM, n (%) 359 (10.3%) 18 (8.7%) 48 (10.1%) 61 (10.2%) 98 (10.2%) 134 (10.7%) 0.93 
Previous MI, n (%) 496 (14.2%) 30 (14.4%) 74 (15.6%) 93 (15.6%) 135 (14.0%) 164 (13.1%) 0.54 
Previous cardiac surgery, n (%) 527 (15.1%) 26 (12.5%) 75 (15.8%) 93 (15.6%) 147 (15.3%) 186 (14.8%) 0.82 
Previous CVA, n(%) 396 (11.3%) 28 (13.5%) 55 (11.6%) 63 (10.6%) 107 (11.1%) 143 (11.4%) 0.85 
Peripheral vascular disease, n (%) 599 (17.2%) 38 (18.3%) 90 (19.0%) 101 (16.9%) 166 (17.3%) 204 (16.3%) 0.73 
Chronic obstructive pulmonary disease, n (%) 445 (12.7%) 33 (15.9%) 76 (16.0%) 84 (14.1%) 125 (13.0%) 127 (10.1%) 0.004 
Coronary artery disease, n (%) 2013 (57.6%) 118 (56.7%) 265 (55.9%) 360 (60.4%) 566 (58.9%) 704 (56.1%) 0.36 
LVEF, (%)  54.8±14.1 54.7±13.5 54.1±14.1 53.9±14.3 55.4±14.0 55.2±14.3 0.27 
Aortic valve area, cm2  0.71 ± 0.24 0.71 ± 0.22 0.72 ± 0.24 0.70 ± 0.26 0.70 ± 0.22 0.71 ± 0.25 0.54 
Mean gradient, mmHg 44.1±19.1 43.6±18.2 44.4±17.0 43.0±18.2 46.2±21.5 43.1±18.6 0.006 
Moderate/severe mitral regurgitation, n (%) 669 (20.4%) 39 (20.5%) 86 (19.8%) 126 (22.5%) 171 (18.8%) 247 (21.0%) 0.51 
Symptoms 
NYHA I or II, n(%) 1165 (34.1%) 41 (19.9%) 139 (29.3%) 205 (34.5%) 309 (33.5%) 471 (38.7%) <0.001 
NYHA III or IV, n(%) 2250 (65.9%) 165 (80.1%) 335 (70.7%) 390 (65.5%) 613 (66.5%) 747 (61.3%) <0.001 
No Angina, n(%) 2696 (77.4%) 138 (67.0%) 330 (69.6%) 497 (83.4%) 746 (78.0%) 985 (78.9%) <0.001 
CCS I or II, n(%) 514 (14.8%) 34 (16.5%) 90 (19.0%) 59 (9.9%) 137 (14.3%) 194 (15.5%) 0.001 
CCS III or IV, n(%) 271 (7.8%) 34 (16.5%) 54 (11.4%) 40 (6.7%) 73 (7.6%) 70 (5.6%) <0.001 
Logistic EuroScore (%) 19.4±13.8 20.9±11.9 20.2±12.9 22.4±16.0 19.4±13.9 17.5±13.1 <0.001 
STS-PROM Score (%) 5.8±4.4 6.8±4.4 7.1±4.7 7.3±5.4.1 5.7± 4.2 4.6±3.6 <0.001 
CCS, Canadian Cardiovascular Society; CVA, Cerebrovascular accident; LVEF, Left ventricular ejection fraction; MI, Myocardial infarction; NYHA, New York Heart Association; PPM, Permanent pacemaker; STS-PROM, The 
Society of Thoracic Surgeons- Predicted Risk Of Mortality.
Table 1
TABLE 2. Procedural characteristics per year of inclusion 
All years 2011 2012 2013 2014 2015 p-value
N = 3493 N = 208 N = 474 N = 596 N = 961 N = 1254 
Device implanted <0.001 
Medtronic CoreValve, n(%) 914 (26.2%) 97 (46.6%) 229 (48.3%) 282 (47.3%) 231 (24.0%) 75 (6.0%) <0.001 
Edwards Sapien XT, n(%) 606 (17.3%) 104 (50.0%) 206 (43.5%) 265 (44.5%) 27 (2.8%) 4 (0.3%) <0.001 
Symetis Acurate, n(%) 98 (2.8%) 0 (0.0%) 16 (3.4%) 19 (3.2%) 19 (2.0%) 44 (3.5%) 0.021 
JenaValve, n(%) 57 (1.6%) 6 (2.9%) 18 (3.8%) 17 (2.9%) 12 (1.2%) 4 (0.3%) <0.001 
SJM Portico, n(%) 87 (2.5%) 0 (0.0%) 1 (0.2%) 4 (0.7%) 18 (1.9%) 64 (5.1%) <0.001 
Medtronic Engager, n(%) 2 (0.1%) 0 (0.0%) 0 (0.0%) 2 (0.3%) 0 (0.0%) 0 (0.0%) 0.045 
Direct Flow Medical, n(%) 34 (1.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 15 (1.6%) 19 (1.5%) 0.001 
Edwards Sapien 3, n(%) 1164 (33.3%) 0 (0.0%) 0 (0.0%) 5 (0.8%) 566 (58.9%) 593 (47.3%) <0.001 
BSC Lotus, n(%) 186 (5.3%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 58 (6.0%) 128 (10.2%) <0.001 
Medtronic Evolut R, n(%) 334 (9.6%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 14 (1.5%) 320 (25.5%) <0.001 
No device*, n(%) 11 (0.3%) 1 (0.5%) 4 (0.8%) 2 (0.3%) 1 (0.1%) 3 (0.2%) 0.19 
Access routes  <0.001 
Femoral, n(%) 3047 (87.2%) 167 (80.3%) 372 (78.5%) 507 (85.1%) 846 (88.0%) 1155 (92.1%) <0.001 
Transapical, n(%) 357 (10.2%) 39 (18.8%) 85 (17.9%) 70 (11.7%) 88 (9.2%) 75 (6.0%) <0.001 
Subclavian, n(%) 34 (1.0%) 2 (1.0%) 5 (1.1%) 7 (1.2%) 11 (1.1%) 9 (0.7%) 0.84 
Direct aortic, n(%) 34 (1.0%) 0 (0.0%) 12 (2.5%) 8 (1.3%) 10 (1.0%) 4 (0.3%) <0.001 
Other, n(%) 21 (0.6%) 0 (0.0%) 0 (0.0%) 4 (0.7%) 6 (0.6%) 11 (0.9%) 0.21 
Procedure location <0.001 
Catheterization laboratory, n(%) 1554 (44.5%) 48 (23.1%) 198 (41.8%) 388 (65.1%) 391 (40.7%) 529 (42.2%) <0.001 
Operating room, n(%) 40 (1.1%) 1 (0.5%) 7 (1.5%) 13 (2.2%) 14 (1.5%) 5 (0.4%) 0.008 
Hybrid room, n(%) 1899 (54.4%) 159 (76.4%) 269 (56.8%) 195 (32.7%) 556 (57.9%) 720 (57.4%) <0.001 
Procedural details 
General anaesthesia, n(%) 1502 (43.0%) 78 (37.5%) 295 (62.4%) 249 (41.8%) 402 (41.8%) 478 (38.1%) <0.001 
Balloon Aortic Valvuloplasty, n(%) 2536 (72.6%) 195 (93.8%) 394 (83.1%) 498 (83.6%) 760 (79.1%) 689 (54.9%) <0.001 
Concomitant procedures 
Percutaneous coronary intervention, n(%) 237 (6.8%) 31 (14.9%) 34 (7.2%) 47 (7.9%) 58 (6.1%) 67 (5.3%) <0.001 
In- hospital course 
Any PRBC Infusion, n(%) 540 (15.5%) 30 (14.4%) 102 (21.5%) 106 (17.8%) 128 (13.3%) 174 (13.9%) <0.001 
Overall In-Hospital Stay (days) 10.1±6.0 11.3±7.3 10.5±5.7 10.4±6.3 9.9±6.0 9.7±5.9 0.002 
*Procedure aborted before device was implanted. PPM, Permanent Pacemaker; PRBC, Packed Red Blood Cells.
Table 2
TABLE 3. Clinical outcomes at 30-day and 1-year after TAVI per year of inclusion 
All years 2011 2012 2013 2014 2015 
Linear trend 
 Hazard Ratio 
(95% CI) 
 p-
value 
Adj. Linear trend 
Hazard Ratio (95% 
CI) 
Adj. Linear 
trend p-value 
N =3493 N = 208 N = 474 N = 596 N = 961 N =1254 
At 30-day 
Mortality 132 (3.8) 12 (5.8) 22 (4.6) 29 (4.9) 38 (4.0) 31 (2.5) 0.82 (0.72-0.93) 0.002 0.89 (0.77-1.02) 0.08 
Cardiac Mortality 122 (3.5) 12 (5.8) 22 (4.6) 25 (4.2) 36 (3.8) 27 (2.2) 0.80 (0.70-0.91) 0.001 0.86 (0.75-0.99) 0.034 
Cerebrovascular Accident 130 (3.8) 7 (3.4) 18 (3.8) 24 (4.1) 33 (3.5) 48 (3.8) 1.01 (0.88-1.16) 0.92 1.03 (0.89-1.19) 0.70 
         Disabling Stroke 69 (2.0) 5 (2.4) 14 (3.0) 13 (2.2) 16 (1.7) 21 (1.7) 0.86 (0.71-1.03) 0.092 0.88 (0.73-1.06) 0.18 
Non-Disabling Stroke 48 (1.4) 1 (0.5) 3 (0.7) 9 (1.5) 13 (1.4) 22 (1.8) 1.29 (0.99-1.67) 0.057 1.32 (1.01-1.72) 0.044 
TIA 13 (0.4) 1 (0.5) 1 (0.2) 2 (0.3) 4 (0.4) 5 (0.4) 1.09 (0.69-1.72) 0.72 1.07 (0.67-1.72) 0.76 
Myocardial Infarction 22 (0.6) 1 (0.5) 3 (0.6) 3 (0.5) 9 (0.9) 6 (0.5) 1.02 (0.72-1.44) 0.90 1.05 (0.73-1.50) 0.79 
Peri-procedural 19 (0.5) 0 (0.0) 3 (0.6) 3 (0.5) 7 (0.7) 6 (0.5) 1.11 (0.76-1.61) 0.60 1.16 (0.78-1.72) 0.46 
Spontaneous 3 (0.1) 1 (0.5) 0 (0.0) 0 (0.0) 2 (0.2) 0 (0.0) 0.65 (0.28-1.50) 0.31 
Acute Kidney Injury 165 (4.8) 24 (11.8) 30 (6.4) 35 (6.0) 38 (4.0) 38 (3.0) 0.79 (0.70-0.89) <0.001 0.84 (0.74-0.95) 0.005 
Stage 1 63 (1.8) 13 (6.4) 13 (2.8) 10 (1.7) 11 (1.2) 16 (1.3) 0.73 (0.61-0.88) 0.001 0.76 (0.62-0.92) 0.005 
Stage 2 29 (0.8) 3 (1.5) 6 (1.3) 5 (0.9) 9 (0.9) 6 (0.5) 0.83 (0.63-1.09) 0.18 0.87 (0.65-1.16) 0.33 
Stage 3 73 (2.1) 8 (3.9) 11 (2.4) 20 (3.4) 18 (1.9) 16 (1.3) 0.81 (0.67-0.96) 0.018 0.88 (0.73-1.06) 0.17 
Bleeding 592 (17.0) 51 (24.7) 92 (19.5) 92 (15.5) 140 (14.6) 217 (17.4) 0.97 (0.91-1.04) 0.45 0.99 (0.92-1.06) 0.69 
     Life Threatening or     
major      
465 (13.4) 41 (19.8) 81 (17.2) 74 (12.5) 120 (12.5) 149 (11.9) 0.90 (0.84-0.97) 0.007 0.92 (0.85-0.99) 0.033 
Minor  133 (3.8) 11 (5.4) 11 (2.4) 19 (3.2) 22 (2.3) 70 (5.6) 1.26 (1.09-1.46) 0.002 1.25 (1.07-1.45) 0.005 
Vascular access site 
complications 
548 (15.7) 38 (18.3) 77 (16.3) 100 (16.8) 136 (14.2) 197 (15.7) 1.01 (0.95-1.09) 0.70 1.01 (0.94-1.08) 0.79 
Major  337 (9.7) 23 (11.1) 48 (10.1) 57 (9.6) 89 (9.3) 120 (9.6) 1.00 (0.91-1.09) 0.96 1.01 (0.92-1.10) 0.89 
Minor 209 (6.0) 15 (7.2) 31 (6.5) 41 (6.9) 43 (4.5) 79 (6.3) 1.03 (0.92-1.15) 0.61 1.01 (0.90-1.13) 0.87 
Pacemaker implantation 641 (18.6) 48 (23.6) 89 (19.1) 103 (17.6) 183 (19.3) 218 (17.6) 0.98 (0.91-1.04) 0.46 0.97 (0.90-1.03) 0.30 
Table 3
At 1-year 
Mortality 437 (12.8) 30 (14.6) 70 (14.8) 94 (15.9) 125 (13.4) 118 (9.7) 0.88 (0.82-0.94) <0.001 0.93 (0.86-1.01) 0.070 
Cardiac Mortality 301 (8.9) 21 (10.4) 51 (10.9) 64 (11.0) 92 (9.9) 73 (6.1) 0.85 (0.78-0.93) <0.001 0.90 (0.82-0.99) 0.033 
Cerebrovascular Accident 166 (4.9) 12 (6.1) 20 (4.3) 30 (5.2) 42 (4.5) 62 (5.1) 1.01 (0.89-1.14) 0.93 1.01 (0.89-1.15) 0.84 
Disabling Stroke 84 (2.5) 6 (2.9) 15 (3.2) 15 (2.6) 22 (2.4) 26 (2.1) 0.89 (0.76-1.05) 0.17 0.91 (0.76-1.07) 0.25 
Non-Disabling Stroke 61 (1.8) 4 (2.2) 3 (0.7) 10 (1.7) 14 (1.5) 30 (2.5) 1.23 (0.98-1.55) 0.071 1.25 (0.99-1.58) 0.063 
TIA 21 (0.6) 2 (1.0) 2 (0.5) 5 (0.9) 6 (0.6) 6 (0.5) 0.94 (0.66-1.32) 0.70 0.91 (0.64-1.29) 0.60 
Myocardial Infarction 45 (1.4) 4 (2.2) 7 (1.6) 5 (0.9) 17 (1.9) 12 (1.0) 0.93 (0.73-1.17) 0.51 0.95 (0.75-1.21) 0.70 
Bleeding 675 (19.6) 56 (27.3) 101 (21.6) 103 (17.6) 173 (18.4) 242 (19.5) 0.99 (0.93-1.05) 0.66 1.00 (0.94-1.06) 0.96 
  Life threatening or major 527 (15.3) 46 (22.5) 87 (18.5) 80 (13.6) 143 (15.2) 171 (13.8) 0.92 (0.86-0.99) 0.024 0.94 (0.88-1.01) 0.095 
      Minor  165 (4.9) 12 (5.9) 15 (3.3) 25 (4.4) 36 (4.0) 77 (6.3) 1.22 (1.07-1.39) 0.003 1.20 (1.05-1.37) 0.007 
Repeat unplanned intervention 80 (2.4) 3 (1.6) 13 (2.9) 9 (1.6) 23 (2.5) 32 (2.7) 1.09 (0.90-1.31) 0.38 1.06 (0.87-1.28) 0.57 
Valve in Valve treatment 16 (0.5) 1 (0.5) 2 (0.4) 5 (0.9) 3 (0.3) 5 (0.4) 0.89 (0.61-1.31) 0.56 0.84 (0.57-1.24) 0.39 
Surgical revision 15 (0.4) 0 (0.0) 2 (0.4) 1 (0.2) 5 (0.5) 7 (0.6) 1.34 (0.83-2.16) 0.23 1.12 (0.70-1.80) 0.64 
Other intervention 51 (1.6) 2 (1.1) 10 (2.2) 4 (0.7) 15 (1.7) 20 (1.7) 1.06 (0.85-1.33) 0.60 1.06 (0.84-1.34) 0.60 
Pacemaker implantation 694 (20.3) 54 (26.8) 98 (21.2) 115 (19.8) 191 (20.3) 236 (19.1) 0.96 (0.90-1.02) 0.23 0.95 (0.90-1.02) 0.15 
Figure1
Figure2
Figure3
Figure4
Figure5
Figure6
